Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs ...
This design is broader than the currently approved KRAS inhibitors, Amgen's Lumakras (sotorasib) and Bristol Myers Squibb's Krazati (adagrasib), which target only the "off" state of KRAS G12C. "While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback